Rocket One's Hoth Therapeutics Ends HT-001 Phase 2a Early, Seeks FDA Input On Potential Phase 3

Rocket One said its biotechnology subsidiary, Hoth Therapeutics, will end the Phase 2a trial of HT-001 early after positive interim efficacy findings. Hoth plans to seek FDA feedback on a potential Phase 3 program; no trial results, timing, or FDA decision were specified.